

Bernhard GrubmÃ¼ller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6580771/publications.pdf>

Version: 2024-02-01

21
papers

653
citations

949033

11
h-index

843174

20
g-index

22
all docs

22
docs citations

22
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
2	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. <i>Molecular Cancer</i> , 2022, 21, 7.	7.9	10
3	Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2022, , 1.	1.0	1
4	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)â€”do we still need contrast media?. <i>European Radiology</i> , 2021, 31, 3754-3764.	2.3	10
5	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 439-447.	2.0	0
6	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	3.3	21
7	Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2489.	1.7	6
8	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. <i>Current Oncology</i> , 2021, 28, 2881-2892.	0.9	16
9	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	0.9	5
10	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	1.1	5
11	Response assessment using [⁶⁸ Ga]Gaâ€PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationâ€resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	1.2	49
12	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
13	Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 713-720.	3.3	46
14	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. <i>Biomarkers</i> , 2020, 25, 268-273.	0.9	6
15	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 52-57.	0.6	4
16	Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 661-667.	0.7	14
17	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2169-2177.	3.3	30
18	Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1063-1072.	3.3	100

#	ARTICLE	IF	CITATIONS
19	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. <i>Clinical Cancer Research</i> , 2018, 24, 6300-6307.	3.2	112
20	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	1.2	22
21	⁶⁴ Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 277-286.	0.7	54